Abstract
JAK1 frameshift mutations may promote cancer cell immune evasion by impeding upregulation of the antigen presentation pathway in microsatellite unstable endometrial cancers (ECs). This study investigated the JAK1 mutation frequency, its functional implication in immune evasion and its prognostic significance in microsatellite unstable EC. Microsatellite instability and three microsatellite repeats within JAK1 were analyzed in 181 ECs. Sixty-two (34%) ECs showed microsatellite instability, of which 22 (35%) had a JAK1 mutation. LMP7, TAP1 and HLA class I protein expression and the presence of CD8-positive T-cells were analyzed in the microsatellite unstable ECs. JAK1 mutant microsatellite unstable ECs showed impaired upregulation of LMP7 (P=0.074) and HLA class I (P<0.001), validated using RNAseq data of the TCGA. TAP1 expression and presence of CD8-positive T-cells were not related to JAK1 mutations. In 198 additional microsatellite unstable ECs, the JAK1 mutation frequency was confirmed but no prognostic significance was found. For, JAK1 wildtype (n=135, 72%) and mutant (n=52, 28%) ECs, 10-year recurrence free rates were 84% and 77% (P=0.301). These observations show that JAK1 mutations are highly frequent in microsatellite unstable EC, not associated with survival, but are associated with impaired upregulation of LMP7 and HLA class I and may therefore facilitate immune escape.
Original language | English |
---|---|
Pages (from-to) | 39885-39893 |
Number of pages | 9 |
Journal | Oncotarget |
Volume | 7 |
Issue number | 26 |
DOIs | |
Publication status | Published - 28-Jun-2016 |
Keywords
- JAK1
- microsatellite instability
- endometrial cancer
- antigen presentation machinery
- HLA class I
- MHC CLASS-I
- MISMATCH-REPAIR DEFICIENCY
- RANDOMIZED-TRIAL
- EXPRESSION
- GENE
- RADIOTHERAPY
- PROGNOSIS
- CARCINOMA
- PATHWAYS
- CELLS